Ilaris Approval History
- FDA approved: Yes (First approved June 17th, 2009)
- Brand name: Ilaris
- Generic name: canakinumab
- Company: Novartis AG
- Treatment for: Cryopyrin-Associated Periodic Syndromes, Juvenile Idiopathic Arthritis
Ilaris (canakinumab) is a human monoclonal antibody for the treatment of children and adults with cryopyrin-associated periodic syndrome (CAPS), and for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older.
FDA Approval History for Ilaris
|May 10, 2013||Ilaris Approved by FDA to Treat Active Systemic Juvenile Idiopathic Arthritis|
|Jun 18, 2009||New Biological Therapy Ilaris Approved In US To Treat Children And Adults With CAPS, A Serious Life-Long Auto-Inflammatory Disease|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.